The data projects an increment in RR-/MDR-TB cases in France from 99 cases in 2024 to 109 cases in 2028. This represents a Compound Annual Growth Rate (CAGR) of approximately 2.5% during the forecast period. Year-on-year analysis shows modest increases between 2% and 3% annually. In comparison to 2023, the series starts with a projection of 99 cases, signaling an upward trend in resistant TB cases in the region. This slow yet steady rise indicates a mounting challenge for healthcare systems to address RR-/MDR-TB control and prevention efforts.
Future trends to watch include the potential impact of improved diagnostic technologies and healthcare policies aimed at combating drug-resistant TB. Monitoring the development and deployment of new treatment regimens can provide vital insights into future caseload reductions or increases. Awareness and responses to TB transmission dynamics in conjunction to socioeconomic factors will also play critical roles in shaping the trend of RR-/MDR-TB cases in France.
